Ahead of continued decision-making around berobenatide’s positioning in obesity and diabetes, Pfizer expanded its argument for the drug at ADA with additional context on tolerability and prior performance. Reporting tied the update to Pfizer’s earlier Metsera acquisition, framing the program as part of its broader push for a long-acting GLP-1 option.